TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The STAR™ Tumor Ablation Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with painful spinal metastatic lesions in thoracolumbar vertebrae (T1-L5) that will be treated with t-RFA using the STAR™ Tumor Ablation System.~* Have signed informed consent~Exclusion Criteria:~* Subjects under 18 years old~* Subjects with heart pacemakers, or other electronic device implants~* Subjects intended for t-RFA in vertebral body levels C1-7

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients receiving Targeted Radiofrequency Ablation (t-RFA) (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia (CML) in chronic or accelerated phase, defined as having any of the following:~  * Peripheral blood (PB) or bone marrow (BM) blasts at least 10% but less than 30%~ * PB or BM blasts and promyelocytes at least 20%~ * PB or BM basophils at least 20%~ * Progressive splenomegaly (at least 10 cm confirmed twice at least 4 weeks apart or 50% increase in splenomegaly over 4 weeks)~ * Clonal evolution defined as the presence of additional cytogenetic abnormalities other than the Ph chromosome~ * Thrombocytopenia (platelet count less than 100,000/mm\^3) unrelated to therapy~ * Hemoglobin less than 7 g/dL unrelated to therapy or bleeding~* Failed prior treatment with imatinib mesylate or intolerant, unable, or unwilling to receive it~* Ineligible for higher-priority or higher-efficacy regimens or protocols~* No blastic phase CML~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Eastern Cooperative Oncology Group (ECOG) 0-2~Life expectancy:~* At least 18 weeks~Hematopoietic:~* See Disease Characteristics~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~Renal:~* Creatinine no greater than 1.5 mg/dL OR~* Creatinine clearance greater than 60 mL/min~Other:~* No other concurrent illness that would preclude study entry~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No more than 2 prior cytotoxic regimens in addition to imatinib mesylate and/or hydroxyurea~* At least 4 weeks since prior chemotherapy and recovered~* Concurrent hydroxyurea and/or anagrelide allowed during first 2 courses~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 4 weeks since prior radiotherapy and recovered~Surgery:~* Not specified~Other:~* See Disease Characteristics~* See Chemotherapy~* At least 24 hours since prior imatinib mesylate~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Diagnosing Extremity Fractures and/or Dislocations Using Ultrasound Presenting to the Emergency Department

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* clinical suspicion of a fracture and/or dislocation of an extremity~* Age Greater than 18 years~* English speaking~* able to give consent~Exclusion Criteria:~* Age less than 18 years, including emancipated minors~* Unstable patients with B/P below 90mmHg systolic~* Open, unstable, or suspected compound fracture~* Physician has reviewed X-Rays and made diagnosis before ultrasound could be done~* X-Rays will not be ordered~* Patient is pregnant~* Patient cannot give own consent~* English is not the patient's primary language

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Those with extremity fractures.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Head Injury Retrieval Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Glasgow Coma Scale score of 3 to 8 due to blunt trauma as measured at the accident scene by the first prehospital team to arrive at the site.~Exclusion Criteria:~* Penetrating trauma~* Age less than 16 years~* No more than 5 casualties at the scene

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard (paramedic) prehospital care (Type: ACTIVE_COMPARATOR): None
- Physician prehospital care (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyperinvasive Approach in Cardiac Arrest

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* minimum of 18 and maximum of 65 years~* witnessed out-of-hospital cardiac arrest of presumed cardiac cause~* minimum of 5 minutes of ACLS performed by emergency medical service team without sustained ROSC~* unconsciousness (Glasgow Coma Score \< 8)~* ECMO team and bed-capacity in cardiac center available.~Exclusion Criteria:~* OHCA of presumed non-cardiac cause~* unwitnessed collapse~* pregnancy~* sustained ROSC within 5 minutes of ACLS performed by EMS team~* conscious patient~* known bleeding diathesis or suspected or confirmed acute or recent intracranial bleeding~* suspected or confirmed acute stroke~* known severe chronic organ dysfunction or other limitations in therapy~* do not resuscitate order or other circumstances making 180 day survival unlikely~* known pre-arrest cerebral performance category CPC ≥ 3.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Hyperinvasive arm (Type: EXPERIMENTAL): Hyperinvasive arm encompasses immediate institution of a mechanical chest compression device (LUCAS) and pre-hospital intraarrest cooling by Rhino-Chill device. Immediately after institution of these two devices the patients will be directly transferred to cardiac center cathlab under continuous CPR. The use of drugs and further defibrillations are on a discretion of the emergency physician. After admission to cathlab, overall status, ROSC presence and ECLS inclusion/exclusion criteria will be evaluated.
- Standard arm (Type: ACTIVE_COMPARATOR): Patients in standard arm will be further managed as per recent ERC guidelines, ie. continued ACLS. The use of drugs and further defibrillations are on a discretion of the emergency physician. If ROSC is attained, patients will be transferred to the same hospital to one of intensive care units, coronary angiography/PCI will be performed only if indicated according to routine practice and mild therapeutic hypothermia will be instituted as soon as possible as per recent guidelines recommendation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Viokase 16, Viokase16 Plus Nexium and Nexium Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females age 18 to 75 years inclusive. Female subjects of child bearing potential or less than two years post-menopausal must use a medically acceptable form of birth control or barrier method and have a negative pregnancy test prior to entry into study.~2. History of abdominal pain associated with chronic pancreatitis~3. Evidence of chronic pancreatitis as manifested by an abnormal secretin test, calcification of the pancreas on plain film, an abnormal CT showing a dilated pancreatic duct and/or atrophy, an abnormal Endoscopicretrogradecholangeopancreatography (ERCP), or diffuse changes on Endoscopic Ultrasound (EUS), fecal elastase \> 100ug/g stool, or serum trypsinogen \> 20ng/ml~   -~Exclusion Criteria:~1. Subjects on enzyme therapy within the last 14 days, proton pump inhibitor (PPI)within the last 7 days, or octreotide within 48 hours.~2. Subjects with known hypersensitivity to pork or exogenous or pancreatic enzymes.~3. Female subjects who are pregnant or lactating~4. Subject use of enzyme therapy other than that called for in this study~5. Subject use of therapeutic amounts of antacids or H2 receptor antagonists during the course of the study.~6. Past history of documented steatorrhea by 72 hour fecal fat determination or current history consistent with steatorrhea -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Nexium alone (Type: ACTIVE_COMPARATOR): Nexium alone is given for one month to be compared to a placebo to Nexium, Viokase 16 plus Nexium and Viokase 16 plus a placebo to Nexium
- Placebo to Nexium, alone (Type: PLACEBO_COMPARATOR): Placebo to Nexium is given instead of Nexium for one month. This will be compared to the Nexium alone, Viokase 16 plus Nexium and Viokase 16 plus placebo to Nexium
- Viokase 16 (pancrelipase) + Nexium (Type: ACTIVE_COMPARATOR): Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month.
- Viokase 16 + placebo to Nexium (Type: PLACEBO_COMPARATOR): Viokase 16 is given with a placebo to Nexium for one month to be compared against Viokase 16 plus Nexium, Nexium alone and Placebo to Nexium alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy and Interferon Alfa Followed by Surgery and/or Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically proven stage I-III squamous cell carcinoma or adenocarcinoma of the esophagus and gastro-esophageal junction Unidimensionally measurable disease~PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-2 Life expectancy: At least 270 days Hematopoietic: WBC greater than 3,000/mm3 Granulocyte count greater than 1,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin, alkaline phosphatase, and SGOT no greater than 2 times upper limit of normal (ULN) Renal: Creatinine less than 2.0 mg/dL Creatinine clearance greater than 50 mL/min Cardiovascular: No serious cardiovascular disease that would preclude study Other: No prior or concurrent malignancy within past 5 years except nonmelanoma skin cancer No serious chronic medical illness that would preclude study No acute or chronic unresolved infection Not pregnant~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Transfusion in Anaemic Cancer Patients Treated With Chemotherapy (HaemOPtimal)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented cancer~* Planned treatment with chemotherapy~* Age older than 18 years~* Informed consent~Exclusion Criteria:~* Heart failure (NYHA 3 and 4)~* Prior serious complications to blood transfusion~* Medical conditions that require special considerations for blood transfusion~* Treatment with erythropoiesis-stimulating agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Haemoglobin (<6.0 mmol/l) (Type: ACTIVE_COMPARATOR): Blood transfusion thresholds:Haemoglobin \< 6.0 mmol/l (9.9 g/dL)
- Haemoglobin (< normal range) (Type: EXPERIMENTAL): Blood transfusion threshold: Haemoglobin \< 7.1 mmol/l (11.7 g/dL) for female and 8.1 mmol/l (13.4 g/dL) for males

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* WOMEN OVER 40 YEARS, UTERINE VOLUME HIGHER THAN 300 ML, MINIMAL ANATOMIC CONDITIONS FOR VAGINAL SURGERY~Exclusion Criteria:~* ACTIVE GYNECOLOGIC MALIGNANCY

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- AROMATASE INHIBITOR (Type: EXPERIMENTAL): this would be compared before and after VAGINAL HYSTERECTOMY
- GNRH ANALOG (Type: ACTIVE_COMPARATOR): this would be compared before and after VAGINAL HYSTERECTOMY

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* unresectable stage IIIB or IV NSCLC~* adequate bone marrow, hepatic, thyroid and renal function~Exclusion Criteria:~* peripheral neuropathy \>= grade 2~* gastrointestinal abnormalities~* known hypersensitivity to retinoids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bexarotene (Type: EXPERIMENTAL): Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Nature Video to Improve Older Adult Health: A Feasibility Study.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Speaks and understands English~* Mild cognitive impairment/mild dementia or normal cognition~* Minor complaints with thinking or memory~* Demonstrate the cognitive capacity to understand and consent to research procedures and to communicate his/her decision~Exclusion Criteria:~* Self-reported phobias that could be triggered by nature-based videos

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- MCI/Mild Dementia (Type: EXPERIMENTAL): Twenty participants will be allocated to this arm if they demonstrate mild impairments in cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences.
- Healthy Older Adults (Type: ACTIVE_COMPARATOR): Participants are allocated to this arm if they demonstrate healthy cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cerebrolysin REGistry Study in Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Clinical diagnosis of acute ischemic stroke~* Patient's independence prior to stroke onset (pre-morbid mRS of 0 or 1)~* Reasonable expectation of successful follow-up (max. 100 days)~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cerebrolysin group (Type: None): Patients who are treated with Cerebrolysin; dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
- Control group (Type: None): Patients who are not treated with Cerebrolysin; treatment follows local clinical practice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Attenuation Corrected Cardiac SPECT Using the GE Hawkeye Camera System

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients referred to the Charlton Nuclear Cardiology Laboratory for stress Tc-99m sestamibi SPECT~Exclusion criteria:~* Prior PTCA or CABG~* Left bundle branch block (LBBB) or paced ventricular rhythm~* Clinically significant valvular heart disease~* Hypertrophic or idiopathic dilated cardiomyopathy~* Atrial fibrillation or frequent atrial or ventricular ectopy (defined as \>20% ectopic beats~* History of MI~* ECG evidence of MI~* Chest circumference \>55 inches

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clinical SPECT (Type: ACTIVE_COMPARATOR): GE Hawkeye Attenuation Correction Camera is being compared to the approved clinical use SPECT camera.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Novel Epidermal Recording and Detection of Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized neonates who already require continuous EEG recording for clinical care~* Parents signed informed consent~* CGA 44 weeks or less~Exclusion Criteria:~* Patient is moribund

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epidermal Electronic System (Type: None): EES, wireless tattoo electrode
- Hydrogel electrode (Type: None): EKG electrode, looking at hairline placement of electrodes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Girls, with Turner syndrome or ISS; height standard deviation score (SDS) ≤ -2~* Bone age ≤ 12 years~* Normal birthweight~* Body mass index (BMI) = 10th-90th percentile~* Normal childhood activity; no physical or other limitations~* Normal, balanced diet (20-40% calories from fat)~Exclusion Criteria:~* Puberty (beyond Tanner Stage 1)~* Diabetes in subject or first degree relative~* Sex steroid therapy~* Chronic conditions requiring medication (treatment for hypothyroidism is permissible)~* Significant systemic disease (pulmonary, cardiac, renal, or other)~* Non-removable metal

- Gender: FEMALE
- Minimum Age: 7 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Turner syndrome (Type: None): Girls, aged 7-14, with short stature due to Turner syndrome and eligible for growth hormone therapy
- Control / idiopathic short stature (Type: None): Girls, aged 7-14, with idiopathic short stature and eligible for growth hormone therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues